Envestnet Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$66.9M Buy
740,002
+408,409
+123% +$34.2M 0.02% 739
2026
Q1
$26.6M Buy
331,593
+118,098
+55% +$9.74M 0.01% 1160
2025
Q4
$18.2M Sell
213,495
-48,092
-18% -$3.95M 0.01% 1268
2025
Q3
$20.3M Sell
261,587
-78,709
-23% -$6.15M 0.01% 1266
2025
Q2
$26.6M Sell
340,296
-56,459
-14% -$4.21M 0.01% 1072
2025
Q1
$28.8M Sell
396,755
-12,080
-3% -$865K 0.01% 970
2024
Q4
$30.3M Sell
408,835
-92,826
-19% -$6.5M 0.01% 953
2024
Q3
$33.1M Sell
501,661
-650,729
-56% -$47.3M 0.01% 917
2024
Q2
$106M Sell
1,152,390
-32,185
-3% -$2.85M 0.04% 428
2024
Q1
$113M Sell
1,184,575
-56,567
-5% -$4.75M 0.04% 409
2023
Q4
$94.6M Buy
1,241,142
+80,025
+7% +$5.57M 0.04% 421
2023
Q3
$80.4M Buy
1,161,117
+116,275
+11% +$9.34M 0.04% 440
2023
Q2
$98.6M Buy
1,044,842
+18,114
+2% +$1.57M 0.04% 350
2023
Q1
$84.9M Buy
1,026,728
+52,072
+5% +$4.09M 0.04% 370
2022
Q4
$72.7M Sell
974,656
-9,437
-1% -$727K 0.04% 379
2022
Q3
$81.3M Buy
984,093
+8,730
+0.9% +$840K 0.05% 326
2022
Q2
$92.7M Sell
975,363
-646,060
-40% -$66.9M 0.05% 303
2022
Q1
$191M Buy
1,621,423
+64,224
+4% +$7.2M 0.1% 184
2021
Q4
$202M Buy
1,557,199
+76,817
+5% +$8.96M 0.1% 174
2021
Q3
$168M Buy
1,480,382
+120,051
+9% +$13.7M 0.09% 194
2021
Q2
$141M Sell
1,360,331
-35,559
-3% -$3.35M 0.08% 216
2021
Q1
$117M Buy
1,395,890
+181,299
+15% +$15.3M 0.08% 214
2020
Q4
$111M Buy
1,214,591
+243,191
+25% +$20.2M 0.08% 186
2020
Q3
$77.5M Buy
971,400
+468,044
+93% +$36.5M 0.07% 222
2020
Q2
$34.8M Buy
503,356
+8,698
+2% +$618K 0.03% 364
2020
Q1
$31.1M Buy
494,658
+2,202
+0.4% +$159K 0.04% 329
2019
Q4
$38.3M Buy
492,456
+6,312
+1% +$493K 0.04% 325
2019
Q3
$35.6M Buy
486,144
+4,953
+1% +$348K 0.04% 332
2019
Q2
$29.6M Buy
481,191
+35,745
+8% +$2.16M 0.04% 343
2019
Q1
$28.4M Sell
445,446
-22,998
-5% -$1.31M 0.04% 341
2018
Q4
$23.9M Buy
468,444
+384,639
+459% +$19.5M 0.04% 320
2018
Q3
$4.86M Sell
83,805
-233,421
-74% -$11.4M 0.01% 428
2018
Q2
$15.4M Buy
317,226
+33,039
+12% +$1.54M 0.04% 234
2018
Q1
$13.2M Sell
284,187
-314,340
-53% -$13.7M 0.04% 182
2017
Q4
$22.5M Buy
598,527
+65,787
+12% +$2.41M 0.05% 212
2017
Q3
$19.4M Buy
532,740
+92,409
+21% +$3.52M 0.05% 223
2017
Q2
$17.4M Buy
440,331
+127,413
+41% +$4.65M 0.05% 244
2017
Q1
$9.81M Buy
312,918
+130,140
+71% +$4.07M 0.03% 367
2016
Q4
$5.71M Buy
182,778
+55,869
+44% +$1.81M 0.02% 498
2016
Q3
$5.1M Sell
126,909
-16,185
-11% -$610K 0.02% 576
2016
Q2
$4.76M Buy
143,094
+50,748
+55% +$1.74M 0.02% 645
2016
Q1
$2.71M Sell
92,346
-14,871
-14% -$410K 0.01% 846
2015
Q4
$2.82M Buy
107,217
+1,875
+2% +$48.7K 0.01% 798
2015
Q3
$2.5M Buy
105,342
+16,944
+19% +$409K 0.01% 855
2015
Q2
$2.1M Buy
88,398
+38,904
+79% +$878K 0.01% 1027
2015
Q1
$1.18M Buy
49,494
+36,126
+270% +$810K 0.01% 1221
2014
Q4
$284K Buy
13,368
+8,082
+153% +$162K ﹤0.01% 892
2014
Q3
$90K Buy
5,286
+5,034
+1,998% +$79.5K ﹤0.01% 1324
2014
Q2
$4K Buy
+252
New +$3.42K ﹤0.01% 2349
2014
Q1
Sell
-1,188
Closed -$13K 2575
2013
Q4
$13K Sell
1,188
-90
-7% -$1.01K ﹤0.01% 1643
2013
Q3
$15K Buy
1,278
+198
+18% +$2.32K ﹤0.01% 1560
2013
Q2
$12K Buy
+1,080
New +$12.8K ﹤0.01% 1599

Other funds holding EW

Envestnet Asset Management's EW Position: Q2 2026 in Review

Envestnet Asset Management increased its Edwards Lifesciences (EW) stake by 123% in Q2 2026, buying an estimated $34.2M and bringing the position to 740,002 shares worth $66.9M. The position accounts for 0.02% of the portfolio, ranked #739.

Envestnet Asset Management first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $202M in Q4 2021. 627 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Envestnet Asset Management held 740,002 shares of Edwards Lifesciences worth $66.9M as of Q2 2026.
  • Envestnet Asset Management bought 408,409 Edwards Lifesciences shares in Q2 2026, an estimated $34.2M.
  • Edwards Lifesciences made up 0.02% of Envestnet Asset Management's portfolio in Q2 2026, its #739 holding.
  • Envestnet Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Envestnet Asset Management's Edwards Lifesciences position peaked at $202M in Q4 2021.
  • 627 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.